Anticancer Drug Pharmacology in Very Young Children

幼儿抗癌药物药理学

基本信息

批准号：
8841683
负责人：
CLINTON F STEWART
金额：
$ 43.35万
依托单位：
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-07-09 至 2016-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8841683
关键词：
1 year old 3 year old Accounting Address Adult Adverse drug event Affect Age Antineoplastic Agents Antitumor Response Applications Grants Body Size Body Weight Brain Neoplasms Characteristics Child Childhood Chronic Clinical Clinical Pharmacology Clinical Protocols Clinical Trials Coupled Cyclophosphamide Data Derivation procedure Development Dose Drug Design Drug Kinetics Drug usage Excretory function Exposure to Genetic Polymorphism Goals Hepatic High Dose Chemotherapy Incidence Individual Infant Infection Intravenous Kidney Knowledge Late Effects Life Liver Malignant Childhood Neoplasm Malignant neoplasm of brain Medical Metabolism Methotrexate Modeling Morbidity - disease rate Myelosuppression Neutropenia Oral Organ Patients Pharmaceutical Preparations Pharmacodynamics Pharmacogenetics Pharmacology Physiological Plasma Population Recommendation Regimen Research Personnel Risk Risk Factors Therapeutic Index Tissues Topotecan Toxic effect absorption age group age related base chemotherapy design dosage evidence base improved infancy infant outcome irradiation patient population pharmacodynamic model pharmacokinetic model response tumor

项目摘要

DESCRIPTION (provided by applicant): Although anti-cancer drugs are widely used in infants and young children with malignant brain tumors, the dosing of these toxic drugs is often scaled based on body size (e.g., BSA or body weight) or arbitrary age cut-offs. This dosing approach does not take into account the many developmental changes that occur in infants and young children. These changes, which include hepatic and renal maturation, may affect the disposition of anticancer drugs, leading to more severe toxicity, particularly myelosuppression, which puts these children at risk of life-threatening infections. Yet the pharmacokinetics and toxicity of many anticancer drugs have not been adequately studied in infants and young children. Thus, we propose to perform clinical pharmacokinetic (PK), pharmacogenetic, and pharmacodynamic (PD) studies of methotrexate (MTX), cyclophosphamide (CTX), and topotecan (TPT) as part of a clinical protocol that treats infants and young children with malignant brain tumors. In this grant application, we propose three hypothesis directed aims: 1.) To characterize the disposition of MTX, oral and intravenous CTX, and oral and intravenous TPT in infants and young children with malignant brain tumors, 2.) To use statistical and mechanistic models to identify PD and PKPD response relationships for anti-cancer drugs in infants and young children, and 3.) To develop dosing regimens for infants and young children to achieve more uniform systemic exposure to anticancer drugs across all pediatric age groups. Collectively, these studies narrow the gap in our understanding of the clinical pharmacology of anti-cancer drugs used to treat infants and young children. Our long-term goal is to determine rational dosing regimens for infants and young children by better understanding the developmental pharmacology of anti-cancer drugs and to apply these regimens to therapy for other childhood malignancies and chronic medical conditions.

描述（申请人提供）：虽然抗癌药物广泛用于患有恶性脑肿瘤的婴幼儿，但这些有毒药物的剂量通常根据体型（例如 BSA 或体重）或任意年龄来调整-offs。这种剂量方法没有考虑到婴儿和幼儿发生的许多发育变化。这些变化，包括肝脏和肾脏的成熟，可能会影响抗癌药物的处置，导致更严重的毒性，特别是骨髓抑制，这使这些儿童面临危及生命的感染的风险。然而，许多抗癌药物的药代动力学和毒性尚未在婴儿和幼儿中得到充分研究。因此，我们建议对甲氨蝶呤 (MTX)、环磷酰胺 (CTX) 和拓扑替康 (TPT) 进行临床药代动力学 (PK)、药物遗传学和药效学 (PD) 研究，作为治疗婴幼儿恶性癌症的临床方案的一部分。脑肿瘤。在本次拨款申请中，我们提出了三个假设导向的目标：1.) 描述患有恶性脑肿瘤的婴儿和幼儿中 MTX、口服和静脉注射 CTX 以及口服和静脉注射 TPT 的处置情况，2.) 使用统计和机制模型来确定婴儿和幼儿抗癌药物的 PD 和 PKPD 反应关系，以及 3.) 制定婴儿和幼儿的给药方案，以实现所有儿科年龄组的抗癌药物的全身暴露更加一致。总的来说，这些研究缩小了我们对用于治疗婴儿和幼儿的抗癌药物的临床药理学的理解差距。我们的长期目标是通过更好地了解抗癌药物的发育药理学来确定婴幼儿的合理给药方案，并将这些方案应用于其他儿童恶性肿瘤和慢性疾病的治疗。